Budget 2025: 'Customs waiver on life-saving drugs won't benefit most patients'

Despite the import duty waiver on life-saving drugs for rare diseases announced in the union budget, patients might not benefit due to high prices maintained by patent monopolies. Activists call for generic production by Indian manufacturers and GST exemption on locally available drugs to effectively reduce prices and provide affordable treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IrBuAto
via IFTTT